AIM: Peroxisome proliferator-activated receptor gamma (PPARgamma) is a therapeutic target for obesity, cancer and diabetes mellitus. In order to develop potent lead compounds for obesity treatment, we screened a natural product library for novel PPARgamma antagonists with inhibitory effects on adipocyte differentiation. METHODS: Surface plasmon resonance (SPR) technology and cell-based transactivation assay were used to screen for PPARgamma antagonists. To investigate the antagonistic mechanism of the active compound, we measured its effect on PPARgamma/RXRalpha heterodimerization and PPARgamma co-activator recruitment using yeast two-hybrid assay, Gal4/UAS cell-based assay and SPR based assay. The 3T3-L1 cell differentiation assay was used to evaluate the effect of the active compound on adipocyte differentiation. RESULTS: A new thiophene-acetylene type of natural product, 7-chloroarctinone-b (CAB), isolated from the roots of Rhaponticum uniflorum, was discovered as a novel PPARgamma antagonist capable of inhibiting rosiglitazone-induced PPARgamma transcriptional activity. SPR analysis suggested that CAB bound tightly to PPARgamma and considerably antagonized the potent PPARgamma agonist rosiglitazone-stimulated PPARgamma-LBD/RXRalpha-LBD binding. Gal4/UAS and yeast two-hybrid assays were used to evaluate the antagonistic activity of CAB on rosiglitazone-induced recruitment of the coactivator for PPARgamma. CAB could efficiently antagonize both hormone and rosiglitazone-induced adipocyte differentiation in cell culture. CONCLUSION: CAB shows antagonistic activity to PPARgamma and can block the adipocyte differentiation, indicating it may be of potential use as a lead therapeutic compound for obesity.
AIM: Peroxisome proliferator-activated receptor gamma (PPARgamma) is a therapeutic target for obesity, cancer and diabetes mellitus. In order to develop potent lead compounds for obesity treatment, we screened a natural product library for novel PPARgamma antagonists with inhibitory effects on adipocyte differentiation. METHODS: Surface plasmon resonance (SPR) technology and cell-based transactivation assay were used to screen for PPARgamma antagonists. To investigate the antagonistic mechanism of the active compound, we measured its effect on PPARgamma/RXRalpha heterodimerization and PPARgamma co-activator recruitment using yeast two-hybrid assay, Gal4/UAS cell-based assay and SPR based assay. The 3T3-L1 cell differentiation assay was used to evaluate the effect of the active compound on adipocyte differentiation. RESULTS: A new thiophene-acetylene type of natural product, 7-chloroarctinone-b (CAB), isolated from the roots of Rhaponticum uniflorum, was discovered as a novel PPARgamma antagonist capable of inhibiting rosiglitazone-induced PPARgamma transcriptional activity. SPR analysis suggested that CAB bound tightly to PPARgamma and considerably antagonized the potent PPARgamma agonist rosiglitazone-stimulated PPARgamma-LBD/RXRalpha-LBD binding. Gal4/UAS and yeast two-hybrid assays were used to evaluate the antagonistic activity of CAB on rosiglitazone-induced recruitment of the coactivator for PPARgamma. CAB could efficiently antagonize both hormone and rosiglitazone-induced adipocyte differentiation in cell culture. CONCLUSION:CAB shows antagonistic activity to PPARgamma and can block the adipocyte differentiation, indicating it may be of potential use as a lead therapeutic compound for obesity.
Authors: H M Wright; C B Clish; T Mikami; S Hauser; K Yanagi; R Hiramatsu; C N Serhan; B M Spiegelman Journal: J Biol Chem Date: 2000-01-21 Impact factor: 5.157
Authors: R Mukherjee; P A Hoener; L Jow; J Bilakovics; K Klausing; D E Mais; A Faulkner; G E Croston; J R Paterniti Journal: Mol Endocrinol Date: 2000-09
Authors: T Yamauchi; H Waki; J Kamon; K Murakami; K Motojima; K Komeda; H Miki; N Kubota; Y Terauchi; A Tsuchida; N Tsuboyama-Kasaoka; N Yamauchi; T Ide; W Hori; S Kato; M Fukayama; Y Akanuma; O Ezaki; A Itai; R Nagai; S Kimura; K Tobe; H Kagechika; K Shudo; T Kadowaki Journal: J Clin Invest Date: 2001-10 Impact factor: 14.808
Authors: Gary Lee; Fabienne Elwood; John McNally; Jennifer Weiszmann; Michelle Lindstrom; Kate Amaral; Motonao Nakamura; Shichang Miao; Ping Cao; R Marc Learned; Jin-Long Chen; Yang Li Journal: J Biol Chem Date: 2002-03-04 Impact factor: 5.157
Authors: Limei Wang; Birgit Waltenberger; Eva-Maria Pferschy-Wenzig; Martina Blunder; Xin Liu; Clemens Malainer; Tina Blazevic; Stefan Schwaiger; Judith M Rollinger; Elke H Heiss; Daniela Schuster; Brigitte Kopp; Rudolf Bauer; Hermann Stuppner; Verena M Dirsch; Atanas G Atanasov Journal: Biochem Pharmacol Date: 2014-07-30 Impact factor: 5.858